Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents

Journal of Anaesthesiology Clinical Pharmacology

关键词: anesthetic drugs;    azithromycin;    covid-19;    dexamethasone;    favipiravir;    hydroxychloroquine;    ivermectin;    nitazoxanide;    remdesivir;    ritonavir;    tocilizumab;   

DOI  :  10.4103/joacp.JOACP_461_20

来源: DOAJ

【 摘 要 】

The corona virus disease 2019 (COVID-19) pandemic has till date (26/7/20) affected 1crore 62 lac 73 thousand 638 people globally with almost 6.5 lakh mortalities. COVID-19 has invaded the operation theatre and intensive care unit (ICU) in a short span of 6 months. It appears inevitable that all of us, as anesthesiologists, have to treat COVID-positive patients, either in the ICU or the operation theatre. Many asymptomatic, presumably noninfected people including frontline health care workers are also consuming potential anticorona viral drugs (such as hydroxychloroquine) prophylactically and may present for surgery. Detailed knowledge of which anesthetic and perioperative care drugs can interact with anti-COVID drugs would be very valuable for pre, intra-, and postoperative management of such patients and COVID-19 positive patients requiring intubation, mechanical ventilation, and ICU-sedation. Powered with this knowledge, anesthesiologists and intensivists can minimize the adverse effects of drug interactions. An extensive literature search using different search engines including Cochrane, Embase, Google Scholar, Scopus, and PubMed for all indexed review articles, original articles, case reports, and referenced webpages was performed to extract the most current and relevant literature on drug-drug interactions for clinicians.

【 授权许可】

Unknown